Skip to main content

Table 1 Clinical information for altered and unaltered groups on cBioPortal

From: Increased expression of YTHDF1 and HNRNPA2B1 as potent biomarkers for melanoma: a systematic analysis

Clinical attributeStatistical testP-valueQ-value
Somatic statusChi squared test1.43 * 10−59.68 * 10−4
Biopsy timeChi squared test2.20 * 10−59.68 * 10−4
CohortChi squared test2.86 * 10−59.68 * 10−4
Tumor stageChi squared test3.34 * 10−59.68 * 10−4
HLA_DPA2Chi squared test1.23 * 10−42.84 * 10−4
Tumor siteChi squared test3.12 * 10−44.71 * 10−4
Mutation countKruskal–Wallis test3.76 * 10−44.71 * 10−4
Disease free statusChi squared test4.02 * 10−44.71 * 10−4
Cancer type detailedChi squared test4.11 * 10−44.71 * 10−4
Oncotree codeChi squared test4.11 * 10−44.71 * 10−4
HLA_DPB2Chi squared test4.70 * 10−44.71 * 10−4
Durable clinical benefitChi squared test4.87 * 10−44.71 * 10−4
RAF_RAS statusChi squared test6.57 * 10−45.49 * 10−4
HLA_DQA2Chi squared test6.68 * 10−45.49 * 10−4
HLA_DRB2Chi squared test7.09 * 10−45.49 * 10−4
Neo-antigen loadKruskal–Wallis test1.24 * 10−39.02 * 10−4
Serum lactate dehydrogenaseKruskal–Wallis test1.75 * 10−30.012
DosageChi squared test2.76 * 10−30.0178
Mutation loadKruskal–Wallis test3.62 * 10−30.021
Treatment responseChi squared test3.82 * 10−30.0211